Jonathan Schoenfeld is an Oncology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 414 publications with 8,388 citations (h-index 45); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
450 Brookline Ave # Dal2-57
Department Of Radiation Oncology
Boston, MA 022155418
Telephone
617-632-3591Provider last certified this registry record 12 Mar 2026.
Clinical trials
- Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
Sponsor: Jonathan Schoenfeld, MD, MPH
- Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
Sponsor: Dana-Farber Cancer Institute
- Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Sponsor: Dana-Farber Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- LANTHEUS MEDICAL IMAGING, INC.Program year20253 payments
- BIOTRONIK INC.Program year20251 payment
- Merck KGaAProgram year20244 payments$17,447openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
100%Corticosteroid100%Mometasone Furoate100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research
2024 - T cell dynamics with neoadjuvant immunotherapy in head and neck cancer
Nature Reviews Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Dennis Selkoe, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”